On January 12, 2024, during CNBC’s “Halftime Report Final Trades,” Joshua Brown from Ritholtz Wealth Management made a noteworthy observation. He mentioned that Uber Technologies, Inc. (NYSE: UBER) shares had reached an unprecedented peak, surpassing the high from February 2021. Joshua expressed his continued confidence in the stock and maintained his long position, stating that he still loves it.
In line with this positive sentiment, Eric Sheridan, an analyst from Goldman Sachs, reiterated a Buy rating on Uber Technologies and raised the price target from $59 to $78. This endorsement further fueled investor optimism, resulting in a 1.7% increase in Uber shares, which closed at $63.47.
Switching gears to the commodities market, Bryn Talkington from Requisite Capital Management highlighted the Sprott Uranium Miners ETF (NYSE: URNM) as a promising investment. Bryn emphasized that uranium had a strong performance in 2023 and predicted another robust year ahead. However, on Thursday, the Sprott Uranium Miners ETF experienced a 3% decline in value. Despite this setback, the price of uranium had surged in October, reaching a 12-year high at $74.48 per pound. Although uranium mining stocks faced a slight setback in the previous month, the higher uranium price enabled miners to resume production.
Moving on to Brenda Vingiello from Sand Hill Global Advisors, she recommended Abbott Laboratories (NYSE: ABT) as her final trade. On Thursday, RBC Capital analyst Shagun Singh maintained an Outperform rating on Abbott Laboratories and raised the price target from $119 to $128. However, Abbott Laboratories saw a minor decrease of 0.3% and closed at $113.50.
Lastly, Jim Lebenthal from Cerity Partners highlighted the remarkable performance of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), which reached an all-time high on Thursday. During the trading session, Vertex Pharmaceuticals saw a 1.5% increase, with shares reaching $430.08. Vertex recently made headlines with the approval of CASGEVY, the first CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia in the Kingdom of Saudi Arabia. This groundbreaking development further solidified the company’s position in the pharmaceutical industry.
ABT Stock Shows Strong Performance on January 12, 2024, with Positive Momentum and Potential for Growth
On January 12, 2024, ABT stock showed a positive performance, trading near the top of its 52-week range and above its 200-day simple moving average. The price of ABT shares increased by $1.09 since the market last closed, representing a rise of 0.96%. ABT stock opened at $114.28, which was $0.77 higher than its previous close. Overall, ABT stock had a strong performance on January 12, 2024. Investors may want to keep an eye on ABT as it continues to show positive momentum and potential for further growth.
ABT Stock Performance on January 12, 2024: Stable Revenue, Net Income, and EPS
On January 12, 2024, the stock performance of ABT showcased a steady outlook. With total revenue of $43.65 billion over the past year and $10.14 billion in the third quarter, ABT has maintained a consistent revenue stream. Similarly, ABT’s net income has remained steady, reporting $6.91 billion over the past year and $1.43 billion in the third quarter. The earnings per share (EPS) for ABT also reflect a stable performance, with an EPS of $3.91 over the past year and $0.82 in the third quarter. Overall, ABT’s stock performance on January 12, 2024, appears to be stable, with consistent total revenue, net income, and EPS. The positive growth in net income and EPS compared to the previous quarter indicates a potential for growth in the future. However, investors should consider conducting further analysis and considering other factors before making any investment decisions.
